Sanyou and Baiyunshan Xihe sign radiopharma deal

7 July 2026

Sanyou Biopharmaceuticals and Baiyunshan Xihe Health Pharmaceutical have signed a strategic cooperation agreement to co-develop novel radiopharmaceuticals and radiodiagnostic products, pairing artificial intelligence (AI)-based molecular discovery with nuclear medicine manufacturing and clinical translation capabilities.

The Chinese companies said the alliance is intended to build an end-to-end innovation chain, running from target molecule discovery through to clinical development of radiopharmaceutical candidates for precision oncology diagnosis and therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical